The aim of the study was to investigate the association between 25(OH)D and metabolic syndrome (MetS), its components and other surrogate markers of CV risk.
Aim of the research

Results
Approximately a quarter of the patients (n=32, 16 men, 6 COGHD) fulfilled the NCEP-ATPІІІ criteria for MetS. Those diagnosed with MetS demonstrated significantly lower 25(OH)D levels compared with the subjects without MetS (11.8 ± 4.5 ng/ml vs. 16.3 ± 8.1 ng/ml, p < 0.0001) ( Figure 1 ). Further on, we analyzed the association between vitamin D status (adequate vs. insufficient and deficient, i.e. 25(OH)D levels ≥ 30 ng/ml vs. < 30 ng/ml) and the individual components of the MetS as well as some other biochemical and anthropometric factors (normal vs. abnormal values), proved to affect CV risk. (Table 1 Correlation analysis of 25(OH)D levels was also performed including some other markers related to atherogenesis, vascular inflammation and endothelial function, such as hs-CRP, adiponectin, ADMA and IMT (Table 2) . No significant associations were observed.
Patients and methods
This cross-sectional study included 129 adults (70 males, 42.1±16.6 years) with GHD [childhood-onset GHD (COGHD): n=54]. Each subject underwent routine biochemical blood testing, anthropometric (body mass index, waist circumference, waist-to-hip ratio, percent body fat, visceral fat area, skeletal muscle mass) and blood pressure measurements. Other CV risk markers were examined in a subsample of the initial population -highsensitivity C-reactive protein, adiponectin and asymmetric dimethylarginine (n=88); intima-media thickness of carotid arteries (n=44). Total serum 25(OH)D was used to assess vitamin D status and was measured by electro-chemiluminescence binding assay (COBAS, Roche Diagnostics International Ltd.; analytical sensitivity -4.01 ng/ml; within-run and intermediate precisions -≤ 6.5% and ≤ 11.5%, respectively). Table 2 Correlation between 25(OH)D levels and makers related to atherogenesis, vascular inflammation and endothelial function
